GENOVIS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.8 SEK | -2.03% |
|
+12.29% | -35.00% |
| 05-15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,578 | 2,062 | 4,779 | 3,008 | 3,404 | 2,259 | - | - |
| Enterprise Value (EV) 1 | 1,563 | 2,018 | 4,698 | 2,935 | 3,281 | 2,149 | 2,153 | 2,114 |
| P/E ratio | 167 x | 315 x | 178 x | 242 x | 55.3 x | 71.9 x | 25.6 x | 21.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 26.1 x | 33.8 x | 51.4 x | 29.4 x | 21.5 x | 16.4 x | 9.6 x | 7.98 x |
| EV / Revenue | 25.8 x | 33.1 x | 50.5 x | 28.7 x | 20.7 x | 15.7 x | 9.15 x | 7.46 x |
| EV / EBITDA | 115 x | 235 x | 155 x | 123 x | 51.3 x | 42 x | 18.4 x | 14.6 x |
| EV / FCF | 196 x | -121 x | 115 x | -618 x | 59.7 x | 68.8 x | 69.7 x | 53.4 x |
| FCF Yield | 0.51% | -0.83% | 0.87% | -0.16% | 1.67% | 1.45% | 1.43% | 1.87% |
| Price to Book | - | 23.7 x | 41.9 x | 23.9 x | 17.9 x | 10.4 x | 8.6 x | 7.39 x |
| Nbr of stocks (in thousands) | 63,100 | 65,466 | 65,466 | 65,466 | 65,466 | 65,466 | - | - |
| Reference price 2 | 25.00 | 31.50 | 73.00 | 45.95 | 52.00 | 34.50 | 34.50 | 34.50 |
| Announcement Date | 20-02-05 | 21-02-11 | 22-02-08 | 23-02-15 | 24-02-15 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 60.55 | 61.03 | 93.02 | 102.4 | 158.2 | 137.3 | 235.3 | 283.2 |
| EBITDA 1 | 13.56 | 8.573 | 30.31 | 23.91 | 63.95 | 51.15 | 117.1 | 145.2 |
| EBIT 1 | 10.07 | 3.14 | 24.54 | 17.28 | 55.8 | 39.25 | 106 | 133.6 |
| Operating Margin | 16.62% | 5.15% | 26.39% | 16.88% | 35.27% | 28.59% | 45.05% | 47.16% |
| Earnings before Tax (EBT) 1 | 9.667 | 2.149 | 24.6 | 7.996 | 54.85 | 39.3 | 104.8 | 55.9 |
| Net income 1 | 9.551 | 6.446 | 24.78 | 11.19 | 61.5 | 31.15 | 40.8 | 45.7 |
| Net margin | 15.77% | 10.56% | 26.64% | 10.93% | 38.87% | 22.69% | 17.34% | 16.14% |
| EPS 2 | 0.1500 | 0.1000 | 0.4100 | 0.1900 | 0.9400 | 0.4800 | 1.350 | 1.597 |
| Free Cash Flow 1 | 7.971 | -16.68 | 40.92 | -4.753 | 54.94 | 31.25 | 30.9 | 39.6 |
| FCF margin | 13.16% | -27.32% | 43.99% | -4.64% | 34.72% | 22.76% | 13.13% | 13.98% |
| FCF Conversion (EBITDA) | 58.77% | - | 134.99% | - | 85.92% | 61.09% | 26.39% | 27.27% |
| FCF Conversion (Net income) | 83.46% | - | 165.15% | - | 89.34% | 100.32% | 75.74% | 86.65% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-05 | 21-02-11 | 22-02-08 | 23-02-15 | 24-02-15 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 42.06 | 32.57 | 21.09 | 22.98 | 25.74 | 71.28 | 29.46 | 30.19 | 27.31 | 40.06 | 31.3 | 32.65 | 32.95 |
| EBITDA 1 | 23.36 | 11.72 | 2.109 | 6.997 | 3.085 | 45.09 | 7.687 | 8.193 | 3.615 | 18.57 | 10.26 | 12.29 | 20.88 |
| EBIT 1 | 21.9 | 10.1 | 0.221 | 4.993 | 1.957 | 43.4 | 5.981 | 5.662 | 0.76 | 15.83 | 7.857 | 9.253 | 17.85 |
| Operating Margin | 52.06% | 31.02% | 1.05% | 21.73% | 7.6% | 60.89% | 20.3% | 18.76% | 2.78% | 39.53% | 25.1% | 28.34% | 54.16% |
| Earnings before Tax (EBT) | 21.83 | - | 0.211 | 5.008 | -7.274 | 43.74 | 6.617 | 4.269 | 0.226 | 15.96 | - | - | - |
| Net income 1 | 22.21 | 12.32 | 0.672 | 5.708 | -7.508 | 43.56 | 15.22 | 3.138 | -0.422 | 12.74 | 6.285 | 6.78 | 3.745 |
| Net margin | 52.8% | 37.81% | 3.19% | 24.84% | -29.17% | 61.12% | 51.65% | 10.4% | -1.55% | 31.81% | 20.08% | 20.77% | 11.37% |
| EPS 2 | 0.3500 | - | 0.0100 | 0.0900 | -0.1100 | 0.6700 | 0.2300 | 0.0500 | -0.0100 | 0.1900 | 1.130 | 1.275 | -0.1050 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-02-08 | 22-04-27 | 22-08-12 | 22-11-15 | 23-02-15 | 23-05-16 | 23-08-24 | 23-11-15 | 24-02-15 | 24-05-15 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 15 | 44.1 | 81.3 | 72.8 | 123 | 109 | 105 | 145 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 7.97 | -16.7 | 40.9 | -4.75 | 54.9 | 31.3 | 30.9 | 39.6 |
| ROE (net income / shareholders' equity) | 31% | 10.5% | 24.6% | 16.9% | 39.9% | 15.1% | 28.5% | 15.5% |
| ROA (Net income/ Total Assets) | - | - | - | 13.8% | - | - | - | - |
| Assets 1 | - | - | - | 81 | - | - | - | - |
| Book Value Per Share 2 | - | 1.330 | 1.740 | 1.920 | 2.910 | 3.310 | 4.010 | 4.670 |
| Cash Flow per Share 2 | - | 0.0600 | 0.6900 | - | 1.030 | 0.5000 | 0.8000 | 0.9000 |
| Capex 1 | - | 20.4 | 4.49 | 3.83 | 12.8 | 7.67 | 12.3 | 14.8 |
| Capex / Sales | - | 33.48% | 4.83% | 3.74% | 8.09% | 5.58% | 5.24% | 5.21% |
| Announcement Date | 20-02-05 | 21-02-11 | 22-02-08 | 23-02-15 | 24-02-15 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
34.5
SEK
Average target price
50.5
SEK
Spread / Average Target
+46.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.00% | 211M | |
| -4.67% | 12.33B | |
| -5.19% | 8.14B | |
| +31.05% | 5.62B | |
| -8.09% | 4.24B | |
| -54.61% | 3.06B | |
| +13.49% | 2.76B | |
| -1.34% | 2.41B | |
| +31.82% | 2.23B | |
| -3.55% | 1.87B |
- Stock Market
- Equities
- GENO Stock
- Financials Genovis AB